Comparing a biosimilar follitropin alfa (Cinnal-f®) with Gonal-f® in women undergoing ovarian stimulation: An RCT


Background: Advances in recombinant DNA technology led to the development of recombinant follitropin alfa. Recombinant human follicle-stimulating hormone products are used to stimulate follicular maturation.

Objective: To compare the efficacy and safety of a biosimilar-candidate recombinant human follicle-stimulating hormone (Cinnal-f® ; CinnaGen, Iran) with the reference product (Gonal-f® ; Merck Serono, Germany) in women undergoing ovarian stimulation for intracytoplasmic sperm injection (ICSI).

Materials and Methods: In this randomized controlled trial, a total sample size of 200 women (age < 35 yr, candidate for ICSI) was calculated. Participants began a pituitary downregulation protocol with buserelin. They received 150 IU daily of either Cinnal-f® or Gonal-f® from the second day of their cycle. The primary outcome of the study was the percentage of metaphase II (MII) oocytes. The secondary outcomes included the number and quality of oocytes retrieved, duration of stimulation, fertilization rate, embryo quality, the number of clinical and ongoing pregnancies, and the incidence of ovarian hyperstimulation syndrome (as an important safety marker).

Results: A total of 208 women were enrolled, of whom, 200 completed the study period. Ovarian stimulation with Cinnal-f® resulted in a comparable percentage of MII oocytes as with Gonal-f® (78.64% vs 80.02%, respectively; p = 0.81). No statistically significant difference was seen in the secondary outcomes between the groups.

Conclusion: Cinnal-f® proved non-inferior to Gonal-f® , based on the percentage of MII oocytes in women aged < 35 yr undergoing ICSI. Our findings confirm that the efficacy and safety profiles of Cinnal-f® and Gonal-f® are similar.

Key words: Follitropin alfa, Biosimilar, Efficacy, Safety, Intracytoplasmic sperm injection.

[1] Sangamithra A, Bhavani Priyadarshini S. An economic analysis of socio-economic variables and treatment cost of infertility. Shanlax Int J Economic 2015; 3: 1–6.

[2] Vander Borght M, Wyns CH. Fertility and infertility: Definition and epidemiology. Clin Biochem 2018; 62: 2–10.

[3] Parsanezhad ME, Jahromi BN, Zare N, Keramati P, Khalili A, Parsa-Nezhad M. Epidemiology and etiology of infertility in Iran: Systematic review and meta-analysis. J Womens Health 2013; 2: 1–6.

[4] Devroey P, Van Steirteghem A. A review of ten years experience of ICSI. Hum Reprod Update 2004; 10: 19–28.

[5] Shu L, Xu Q, Meng Q, Dai X, Zhang Y, Zhou W, et al. Clinical outcomes following long GnRHa ovarian stimulation with highly purified human menopausal gonadotropin plus rFSH or rFSH in patients undergoing in vitro fertilization-embryo transfer: A multi-center randomized controlled trial. Ann Transl Med 2019; 7: 146–166.

[6] Strowitzki T, Kuczynski W, Mueller A, Bias P. Safety and efficacy of Ovaleap® (recombinant human follicle-stimulating hormone) for up to 3 cycles in infertile women using assisted reproductive technology: A phase 3 open-label follow-up to main study. Reproductive Biology and Endocrinology 2016; 14: 31–45.

[7] Matorras R, Osuna C, Exposito A, Crisol L, Pijoan JI. Recombinant FSH versus highly purified FSH in intrauterine insemination: Systematic review and metanalysis. Fertil Steril 2011; 95: 1937–1942.e3.

[8] Vegetti W, Alagna F. FSH and folliculogenesis: From physiology to ovarian stimulation. Reprod Biomed Online 2006; 12: 684–694.

[9] Lispi M, Bassett R, Crisci C, Mancinelli M, Martelli F, Ceccarelli D, et al. Comparative assessment of the consistency and quality of a highly purified FSH extracted from human urine (urofollitropin) and a recombinant human FSH (follitropin alpha). Reprod Biomed Online 2006; 13: 179–193.

[10] Bergh C, Howles CM, Borg K, Hamberger L, Josefsson B, Nilsson L, et al. Recombinant human follicle stimulating hormone (r-hFSH; Gonal-F) versus highly purified urinary FSH (Metrodin HP): Results of a randomized comparative study in women undergoing assisted reproductive techniques. Hum Reprod 1997; 12: 2133–2139.

[11] Imthurn B, Macas E, Rosselli M, Keller PJ. Endocrinology: Nuclear maturity and oocyte morphology after stimulation with highly purified follicle stimulating hormone compared to human menopausal gonadotrophin. Hum Reprod 1996; 11: 2387–2391.

[12] Hossein Rashidi B, Sarvi F, Shahrokh Tehrani E, Zayeri F, Movahedin M, Khanafshar N. The effect of HMG and recombinant human FSH on oocyte quality: A randomized single-blind clinical trial. Eur J Obstet Gynecol Reprod Biol 2005; 120: 190–194.

[13] Committee for Medicinal Products for Human Use (CHMP). Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human follicle stimulating hormone (r-hFSH). Available at: GB/document_library/Scientific_guideline/2013/ 03/WC500139624.pdf.

[14] Rettenbacher M, Andersen AN, Garcia-Velasco JA, Sator M, Barri P, Lindenberg S, et al. A multi-centre phase 3 study comparing efficacy and safety of Bemfola® versus Gonal-f® in women undergoing ovarian stimulation for IVF. Reprod Biomed Online 2015; 30: 504–513.

[15] Recombinant Human FSH Study Group. Clinical assessment of recombinant human follicle-stimulating hormone in stimulating ovarian follicular development before in vitro fertilization. Fertil Steril 1995; 63: 77–86.

[16] Franco JG, Baruffi RL, Coelho J, Mauri AL, Petersen CG, Garbellini E. A prospective and randomized study of ovarian stimulation for ICSI with recombinant FSH versus highly purified urinary FSH. Gynecol Endocrinol 2000; 14: 5–10.

[17] Hoomans EH, Andersen AN, Loft A, Leerentveld RA, van Kamp AA, Zech H. A prospective, randomized clinical trial comparing 150 IU recombinant follicle stimulating hormone (Puregon®) and 225 IU highly purified urinary follicle stimulating hormone (Metrodin-HP®) in a fixed-dose regimen in women undergoing ovarian stimulation. Hum Reprod 1999; 14: 2442–2447.

[18] Strowitzki T, Kuczynski W, Mueller A, Bias P. Randomized, active-controlled, comparative phase 3 efficacy and safety equivalence trial of Ovaleap® (recombinant human follicle-stimulating hormone) in infertile women using assisted reproduction technology (ART). Reprod Biol Endocrinol 2016; 14: 1–12.